|Bid||10.42 x 1200|
|Ask||10.70 x 1300|
|Day's range||10.08 - 10.70|
|52-week range||7.34 - 58.37|
|Beta (5Y monthly)||N/A|
|PE ratio (TTM)||N/A|
|Earnings date||29 Mar 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||23.00|
Frequency Therapeutics, Inc. (FREQ) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
A risky path lies ahead for the clinical-stage biotech, which saw disappointing results for FX-322 in March 2021. Can management learn from its mistakes?
Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases, today announced the expansion of its clinical development team with the addition of Jeffery T. Lichtenhan, Ph.D., a leading expert in hearing diagnostics and measurement.